For ANDA and 505(b)(2) programs, demonstrating bioequivalence to a reference product is often the single biggest bottleneck in generic drug development, costly clinical studies, long timelines, and in some cases, real ethical constraints around who can be enrolled.
In silico modeling and simulation is increasingly being used to predict drug behavior in the human body, identify safety concerns earlier, and optimize dosing regimens, helping reduce reliance on traditional BE studies while still generating the kind of robust, regulatory-ready evidence agencies expect.
At InSilicoMinds, this is exactly where we work. We help generics companies build PBPK-based virtual bioequivalence strategies for both ANDA and 505(b)(2) submissions, accelerating timelines, reducing costs, and strengthening regulatory confidence in your dossier.
If bioequivalence is slowing down your generic pipeline, let’s talk. 🤝
